Mycamine en es it fr

Mycamine Brand names, Mycamine Analogs

Mycamine Brand Names Mixture

  • No information avaliable

Mycamine Chemical_Formula


Mycamine RX_link

Mycamine fda sheet

Mycamine FDA

Mycamine msds (material safety sheet)

Mycamine MSDS

Mycamine Synthesis Reference

No information avaliable

Mycamine Molecular Weight

1029.26 g/mol

Mycamine Melting Point

No information avaliable

Mycamine H2O Solubility

No information avaliable

Mycamine State


Mycamine LogP

No information avaliable

Mycamine Dosage Forms

Solution (sterile, non-pyrogenic, with pH 3.5 to 5.0 containing mivacurium chloride equivalent to 2 mg/mL mivacurium in water for injection)

Mycamine Indication

For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Mycamine Pharmacology

Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by mivacurium is readily antagonized by anticholinesterase agents. The deeper the level of neuromuscular block at reversal, the longer the time required for recovery of neuromuscular function and the greater the dose of anticholinesterase agent required. Because spontaneous recovery after mivacurium is rapid, routine reversal may not always result in a clinical benefit.

Mycamine Absorption

No information avaliable

Mycamine side effects and Toxicity

Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.

Mycamine Patient Information

Mycamine Organisms Affected

Humans and other mammals